Eyenovia, Inc.’s Post

Glaucoma treatment options may include medications, surgery, or a combination of treatments. That's why regular eye exams are so important. #imprimisrx #TreatmentOptions #glaucomaearlydetection #EyeExams #GlaucomaAwareness #Pharmaceuticals

An innovative solution.

Unlike some other treatment options, TMJ physical therapy is non-invasive. It avoids the need for surgery or pharmaceutical interventions, making it an attractive and low-risk option for many individuals seeking relief from TMJ-related symptoms. #TMJTherapy #JawPainRelief #TMJTreatment #PhysicalTherapyJaw #JawHealthMatters #TMJRecovery #PainFreeJaw #TherapeuticJawCare #TMJReliefJourney #HealthyJawMovement

Medcura, Inc. has closed a private placement with aggregate gross proceeds of $22.4 million. We will use these funds to accelerate the development of our lead surgical product, LifeGel™ Absorbable Hemostatic Gel, complete pre-clinical testing of the product, and file an Investigational Device Exemption for LifeGel with the U.S. FDA to support an investigational study focused on stopping bleeding in spinal surgery. Current hemostatic agents swell and can cause neurological issues, including paralysis, when used in confined spaces routinely addressed in spinal surgery.   Medcura’s Chief Executive Officer Jim Buck stated, “We remain highly encouraged by the continued momentum and pace of successes around our Life™ platform of innovative surgical hemostatic agents. Our new and existing investor partners understand, and are aligned with, the Company’s strategy to seismically transform the $2.8 billion worldwide biosurgery market for hemostatic agents. This funding support is timely and crucial to further advance our progress into a pivotal clinical trial and global commercialization of the platform’s lead product, LifeGel.”  #biotech #surgery #Medcura

Current treatment options for #pterygium, an #OcularDisease, include over-the-counter topical treatments and surgery — both with considerable drawbacks. That’s why there’s an urgent need for more effective, lasting alternatives.      While there are no FDA-approved drugs for pterygium, Cloudbreak is developing the first potential therapy for this condition, which is now in Phase 3 clinical trials. Learn more about our work: https://lnkd.in/e_UnxjTr 

Optimizing #dentalimplant esthetics in the anterior zone requires proper diagnosis and treatment planning that synthesizes #dentalanatomy, #softtissue biologics, and #dentalmaterial choices. This #JPDDigital presents evidence-based and systematic approaches to effectively plan, treat, and manage implant surgery and prosthetics: https://lnkd.in/d2_sRZcE

Are you not happy about your wrinkles and age lines? Are you looking for a solution, that costs a fraction of cosmetic surgery, is none invasive and doesn't use pharmaceutical? Well look no further LifeWave Y-Age #patches are here. #WhatsApp me on +27836367663 , message me or leave a comment below and I will share the secret with you.

RationalStat has recently published a comprehensive market report on - “Global Glaucoma Surgery Devices Market Analysis and Forecast 2019-2030”. As per the analysis, the global glaucoma surgery devices market is to grow at a CAGR of 5.8% over the forecast period of 2019-2030. 📈 Increasing prevalence of #glaucoma worldwide, the growing aging #population, and the technological advancements in glaucoma surgery devices are surging the #marketgrowth. 🌎 North America is the largest market for glaucoma surgery devices, followed by Europe and Asia Pacific. The global glaucoma surgery devices market is dominated by key players, including: 🔹 Alcon 🔹 Glaukos Corporation 🔹 Allergan 🔹 Lumibird Medical - Quantel Medical & Ellex 🔹 New World Medical 🔹 Lumenis 🔹 Iridex 🔹 Bausch Health Companies Inc. 🔹 Topcon Corporation 🔹 Santen Pharmaceutical 🔗 To get detailed #marketinsights, data, and supplier assessment, request a sample report at: https://lnkd.in/d4Kd26Qy 📧 For more, please reach out to sales@rationalstat.com or call: +44 203-287-1245 or +1 302-803-5429 #RationalStat #marketanalysis #markettrends #industryanalysis #industryinsights #investment #marketreport #researchreport #industryreport #globalmarket #glaucoma #device #health #healthcare #medical #medicalindustry

Ameloblastoma is a slow-growing tumor that develops in the space behind our molar or back teeth, and often results in an enlarged jaw and facial deformities. For most, the standard therapy requires reconstructive surgery to replace the bone and tissues removed and prevent visible disfigurement. Following recent successful clinical trials and FDA approval, anti-BRAF inhibitor therapy, which spares the trauma of aesthetic deformities as well as functional and psychological impairments, offers a significant improvement in outcomes for patients. Click here to learn more: https://lnkd.in/dCHaPpCH